Skip to search formSkip to main contentSkip to account menu

Mitoxantrone

Known as: 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone, 1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione, Mitoxantronum 
An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA… 
National Institutes of Health

Related topics

Related topics

49 relations

Broader (2)

Antineoplastic Agentsanthracene

Narrower (26)

BBR 2577BBR3378CL 232315DMV regimen
Congestive heart failureIn BloodMammary NeoplasmsMitoxantrone Hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Review
2010
Review
2010
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Highly Cited
2008
Highly Cited
2008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
PURPOSE The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each… 
Highly Cited
2004
Highly Cited
2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
BACKGROUND Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory… 
Highly Cited
2004
Highly Cited
2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent… 
Highly Cited
2002
Highly Cited
2002
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial
Highly Cited
1999
Highly Cited
1999
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
Reports of multiple distinct mitoxantrone-resistant sublines without overexpression of P-glycoprotein or the multidrug-resistance… 
Highly Cited
1999
Highly Cited
1999
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
PURPOSE Approximately 40,000 men die each year of hormone-refractory prostate cancer (HRPC). The results of treatment with… 
Highly Cited
1998
Highly Cited
1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Rituximab, a chimeric monoclonal antibody that binds specifically to the CD20 antigen, induced objective responses in 50% of… 
Highly Cited
1996
Highly Cited
1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
PURPOSE To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License